SB Capital Management Inc Makes New Investment in Oramed Pharmaceuticals Inc. $ORMP

Posted by Francis Steltz on Jun 19th, 2026

SB Capital Management Inc acquired a new stake in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Free Report) during the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 1,900,000 shares of the biotechnology company’s stock, valued at approximately $5,415,000. Oramed Pharmaceuticals makes up about 2.0% of SB Capital Management Inc’s holdings, making the stock its 18th biggest position.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Marshall Wace LLP bought a new stake in shares of Oramed Pharmaceuticals during the fourth quarter worth $738,000. BML Capital Management LLC boosted its holdings in Oramed Pharmaceuticals by 2.7% in the third quarter. BML Capital Management LLC now owns 3,167,231 shares of the biotechnology company’s stock valued at $8,361,000 after acquiring an additional 83,978 shares during the last quarter. HRT Financial LP bought a new position in Oramed Pharmaceuticals in the fourth quarter valued at about $131,000. Quadrature Capital Ltd acquired a new stake in Oramed Pharmaceuticals in the fourth quarter worth about $119,000. Finally, Squarepoint Ops LLC raised its holdings in Oramed Pharmaceuticals by 95.1% during the 4th quarter. Squarepoint Ops LLC now owns 58,272 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 28,406 shares during the last quarter. 12.73% of the stock is owned by institutional investors and hedge funds.

Oramed Pharmaceuticals Price Performance

Shares of NASDAQ:ORMP opened at $3.88 on Friday. The firm’s 50 day simple moving average is $3.95 and its 200 day simple moving average is $3.51. Oramed Pharmaceuticals Inc. has a fifty-two week low of $1.98 and a fifty-two week high of $5.01. The company has a market capitalization of $158.81 million, a price-to-earnings ratio of 1.50 and a beta of 1.26.

Oramed Pharmaceuticals (NASDAQ:ORMP – Get Free Report) last issued its quarterly earnings data on Friday, March 27th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. Equities research analysts expect that Oramed Pharmaceuticals Inc. will post 0.71 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Oramed Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, June 11th. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat, Oramed Pharmaceuticals currently has an average rating of “Hold”.

Read Our Latest Stock Analysis on ORMP

About Oramed Pharmaceuticals

(Free Report)

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.